Quantcast

Latest Protease Stories

2009-07-07 07:30:00

SOUTH SAN FRANCISCO, Calif., July 7 /PRNewswire/ -- Catalyst Biosciences, Inc. today announced the signing of an exclusive worldwide research and license agreement with MedImmune, the global biologics unit of AstraZeneca plc, to develop novel engineered proteases that specifically degrade or modulate two targets, one of which will address inflammatory and autoimmune diseases. Catalyst will receive undisclosed upfront licensing fees, full-time employee (FTE) support and milestone payments...

2009-06-03 15:00:00

BRISBANE, Calif., June 3 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that Daniel Welch, Chairman, Chief Executive Officer and President of InterMune, will present at the Goldman Sachs 30th Annual Global Healthcare Conference in New York on June 9, 2009 at 2:35 p.m. ET. To access a live audio webcast of the presentation, investors and other interested parties may log on to the investor relations page of InterMune's corporate website at www.intermune.com. The...

2009-04-21 06:00:00

BRISBANE, Calif., April 21 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) announced today that it will release first quarter 2009 financial results on Thursday, April 30, 2009 at 4:00 p.m. Eastern time. A live conference call and webcast will be hosted by InterMune at 4:30 p.m. Eastern time that same day. To access the live teleconference, dial 888-799-0528 (U.S.) or 973-200-3372 (international), conference ID# 95970767. To access the webcast, please log on to the company's...

2009-03-30 06:00:00

BRISBANE, Calif., March 30 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that Daniel G. Welch, Chairman, Chief Executive Officer and President of InterMune, will present at Citi's 4th Annual Biotech Day in New York City on April 1, 2009 at 10:40 a.m. EDT. To access a live audio webcast of the presentation, investors and other interested parties may log on to the investor relations page of InterMune's corporate website at www.intermune.com. The company recommends...

2009-03-24 07:30:00

SOUTH SAN FRANCISCO, Calif., March 24 /PRNewswire/ -- Catalyst Biosciences, Inc., a pioneer in the discovery and development of engineered proteases known as Alterase(TM) therapeutics, has appointed four new members to the company's Scientific Advisory Board (SAB). Robert J. Fletterick, Ph.D., David Ginsburg M.D., Guy S. Salvesen, Ph.D., and Gregory Stahl, Ph.D., join initial members Shaun Coughlin, M.D., Ph.D., Charles Craik, Ph.D., and James Wells, Ph.D. "We are pleased to welcome this...

2009-03-18 11:49:00

BRISBANE, Calif., March 18 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that five abstracts from clinical and in-vitro studies of ITMN-191 (R7227) and the company's research programs related to the hepatitis C virus (HCV) have been accepted for presentation at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL, April 22-26, 2009 in Copenhagen, Denmark). The abstracts are expected to be available at www.easl.ch. ITMN-191 is an HCV...

2009-03-13 15:00:00

BRISBANE, Calif., March 13 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that Daniel G. Welch, Chairman, Chief Executive Officer and President of InterMune, will present at the Cowen and Company 29th Annual Health Care Conference in Boston on March 17, 2009 at 3:10 p.m. EDT. To access a live audio webcast of the presentation, investors and other interested parties may log on to the investor relations page of InterMune's corporate website at www.intermune.com. The...

2009-02-20 07:00:00

BRISBANE, Calif., Feb. 20 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) announced today that it will release fourth quarter and full-year 2008 financial results on Thursday, February 26, 2009 at 4:00 p.m. Eastern time. A live conference call and webcast will be hosted by InterMune at 4:30 p.m. Eastern time that same day. To access the live teleconference, dial 888-799-0528 (U.S.) or 973-200-3372 (international), conference ID# 86755415. To access the webcast, please log on to...

2009-01-09 15:01:00

BRISBANE, Calif., Jan. 9 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that it will conduct a conference call and webcast on Monday, January 12 at 8:30 a.m. EST to discuss results from its Phase 1b, 14-day study of hepatitis C virus (HCV) protease inhibitor ITMN-191 (R7227) in combination with Pegasys(R) (interferon alfa-2a) and Copegus(R) (ribavirin) in patients chronically infected with HCV genotype 1. ITMN-191 is being developed in collaboration with Roche....

2008-11-14 09:00:34

BRISBANE, Calif., Nov. 14 /PRNewswire-FirstCall/ -- InterMune, Inc. today announced that Daniel G. Welch, Chairman, Chief Executive Officer and President of InterMune, will present at Lazard Capital Markets 5th Annual Healthcare Conference on November 18, 2008 at 3:10 p.m. EST. To access a live audio webcast of the presentation, investors and other interested parties may log on to the investor relations page of InterMune's corporate website at http://www.intermune.com/. The company...


Word of the Day
omadhaun
  • A fool; a simpleton: a term of abuse common in Ireland and to a less extent in the Gaelic-speaking parts of Scotland.
This word is partly Irish in origin.